Absci Corporation showcases AI-driven antibody discovery and new clinical-stage drug programs

Reuters01-15

Absci Corporation showcases AI-driven antibody discovery and new clinical-stage drug programs

Absci Corporation presented new developments at the 44th Annual J.P. Morgan Healthcare Conference, highlighting progress in generative AI-driven drug discovery. The company showcased its industrialized platform that combines AI and wet-lab capabilities to accelerate and reduce the cost of drug discovery, moving from initial code to clinical-stage programs in as little as 24 months. The presentation detailed three clinical-stage programs, including ABS-201 for androgenetic alopecia, ABS-201 for endometriosis, and ABS-101 for inflammatory bowel disease $(IBD)$. ABS-201, targeting PRLR inhibition, was noted as a potential new category of therapy for hair regrowth, aiming to address significant unmet needs in androgenetic alopecia with an innovative approach distinct from current treatments. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Absci Corporation published the original content used to generate this news brief on January 14, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2603623062?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-15 08:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2603623062","market":"us","top_or_hot":-1,"title":"Absci Corporation showcases AI-driven antibody discovery and new clinical-stage drug programs","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Absci Corporation showcases AI-driven antibody discovery and new clinical-stage drug programs\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Absci Corporation presented new developments at the 44th Annual J.P. Morgan Healthcare Conference, highlighting progress in generative AI-driven drug discovery. The company showcased its industrialized platform that combines AI and wet-lab capabilities to accelerate and reduce the cost of drug discovery, moving from initial code to clinical-stage programs in as little as 24 months. The presentation detailed three clinical-stage programs, including ABS-201 for androgenetic alopecia, ABS-201 for endometriosis, and ABS-101 for inflammatory bowel disease <a href=\"https://laohu8.com/S/IBD\">$(IBD)$</a>. ABS-201, targeting PRLR inhibition, was noted as a potential new category of therapy for hair regrowth, aiming to address significant unmet needs in androgenetic alopecia with an innovative approach distinct from current treatments. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Absci Corporation published the original content used to generate this news brief on January 14, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Absci Corporation showcases AI-driven antibody discovery and new clinical-stage drug programs</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAbsci Corporation showcases AI-driven antibody discovery and new clinical-stage drug programs\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-15 08:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Absci Corporation showcases AI-driven antibody discovery and new clinical-stage drug programs\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Absci Corporation presented new developments at the 44th Annual J.P. Morgan Healthcare Conference, highlighting progress in generative AI-driven drug discovery. The company showcased its industrialized platform that combines AI and wet-lab capabilities to accelerate and reduce the cost of drug discovery, moving from initial code to clinical-stage programs in as little as 24 months. The presentation detailed three clinical-stage programs, including ABS-201 for androgenetic alopecia, ABS-201 for endometriosis, and ABS-101 for inflammatory bowel disease <a href=\"https://laohu8.com/S/IBD\">$(IBD)$</a>. ABS-201, targeting PRLR inhibition, was noted as a potential new category of therapy for hair regrowth, aiming to address significant unmet needs in androgenetic alopecia with an innovative approach distinct from current treatments. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Absci Corporation published the original content used to generate this news brief on January 14, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ABSI","symbol_name":"Absci Corporation.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260115:nNDL2mtfp2:1","article_id":"2603623062","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2603623062","pubTimestamp":1768436557,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Absci Corporation presented new developments at the 44th Annual J.P. Morgan Healthcare Conference, highlighting progress in generative AI-driven drug discovery. The company showcased its industrialized platform that combines AI and wet-lab capabilities to accelerate and reduce the cost of drug discovery, moving from initial code to clinical-stage programs in as little as 24 months. The presentation detailed three clinical-stage programs, including ABS-201 for androgenetic alopecia, ABS-201 for endometriosis, and ABS-101 for inflammatory bowel disease . ABS-201, targeting PRLR inhibition, was noted as a potential new category of therapy for hair regrowth, aiming to address significant unmet needs in androgenetic alopecia with an innovative approach distinct from current treatments. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ABSI":"Absci Corporation.","BK4139":"生物科技","BK4539":"次新股","BK4121":"生命科学工具和服务"},"translate_title":"Absci Corporation展示人工智能驱动的抗体发现和新的临床阶段药物项目","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ABSI":0.9},"content_text":"Absci Corporation showcases AI-driven antibody discovery and new clinical-stage drug programs\n    \n\n        Absci Corporation presented new developments at the 44th Annual J.P. Morgan Healthcare Conference, highlighting progress in generative AI-driven drug discovery. The company showcased its industrialized platform that combines AI and wet-lab capabilities to accelerate and reduce the cost of drug discovery, moving from initial code to clinical-stage programs in as little as 24 months. The presentation detailed three clinical-stage programs, including ABS-201 for androgenetic alopecia, ABS-201 for endometriosis, and ABS-101 for inflammatory bowel disease $(IBD)$. ABS-201, targeting PRLR inhibition, was noted as a potential new category of therapy for hair regrowth, aiming to address significant unmet needs in androgenetic alopecia with an innovative approach distinct from current treatments. You can access the full presentation through the link below.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Absci Corporation published the original content used to generate this news brief on January 14, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.1","shortVersion":"4.36.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2603623062","isCrawlerRequest":true}